Recombinantly modified plasmin

Details Recombinantly modified plasmin Recombinantly modified plasmin

2005-04-21

2011-10-11

Nguyen, Quang (Department: 1633)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C536S023400, C435S320100, C435S455000

Reexamination Certificate

active

08034913

ABSTRACT:
Polynucleotides and polypeptides relating to a recombinantly-modified plasmin(ogen) molecule are provided. The plasmin(ogen) molecule has a single kringle domain N-terminal to the activation site present in the native human plasminogen molecule, and exhibits lysine-binding and significant enzymatic characteristics associated with the native enzyme.

REFERENCES:
patent: 4631211 (1986-12-01), Houghten et al.
patent: 4652639 (1987-03-01), Stabinsky
patent: 4774087 (1988-09-01), Wu
patent: 5149533 (1992-09-01), Mulvihill et al.
patent: 6218517 (2001-04-01), Suzuki
patent: 6312893 (2001-11-01), Van Ness
patent: 6355243 (2002-03-01), Novokhatny
patent: 6444422 (2002-09-01), Van Ness
patent: 6538103 (2003-03-01), Ji et al.
patent: 6613508 (2003-09-01), Van Ness
patent: 6623928 (2003-09-01), Van Ness
patent: 6664112 (2003-12-01), Mulligan
patent: 6946438 (2005-09-01), Nagai et al.
patent: 7253264 (2007-08-01), Lauffer et al.
patent: 2003/0012778 (2003-01-01), Zimmerman
patent: 2003/0026798 (2003-02-01), Zimmerman
patent: 2003/0147877 (2003-08-01), Trese et al.
patent: 2003/0175264 (2003-09-01), Jesmok
patent: 2005/0118158 (2005-06-01), Pakola et al.
patent: 2005/0124036 (2005-06-01), Susilo
patent: 2045869 (1991-12-01), None
patent: WO 97/27331 (1997-07-01), None
patent: WO 99/05322 (1999-02-01), None
patent: WO 01/94366 (2001-12-01), None
patent: WO 02/50290 (2002-06-01), None
patent: WO 03/054232 (2003-07-01), None
patent: WO 2004/052228 (2004-06-01), None
patent: WO 2005/105990 (2005-11-01), None
patent: WO 2007/047874 (2007-04-01), None
patent: WO 2009/073471 (2009-06-01), None
Hunt et al. Simplified recombinant plasmin: Production and functional comparison of a novel thrombolytic molecule with plasma-derived plasmin. Thromb. Haemost 100:413-419, 2008.
Andrianov, S.I., et al., “Peculiarities of Hydrolytic Action of Plasmin, Miniplasmin, Microplasmin and Trypsin on Polymeric Fibrin,”Ukr. Biokhim. Zh., 64(3): 14-20 (1992).
Anonick, P., et al., “Regulation of Plasmin, Miniplasmin and Streptokinase—Plasmin Complex by—α-2-Antiplasmin, α-2- Macroglobulin, and Antithrombin III in the Presence of Heparin,”Thrombosis Res., 59: 449-462 (1990).
Bennett, D., et al., “Kinetic Characterization of the Interaction of Biotinylated Human Interleukin 5 with an Fc Chimera of its Receptor α Subunit and Development of an ELISA Screening Assay using Real-Time Interaction Biosensor Analysis,”J. Molecular Recognition, 8: 52-58 (1995).
Bowie, J.U., et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions,”Science, 247: 1306-1310 (1990).
Burck, P.J., et al., “Characterization of a Modified Human Tissue Plasminogen Activator Comprising a Kringle-2 and a Protease Domain, ”J Biol. Chem., 265(9): 5170-5177 (1990).
Cao, Y., et al., “Kringle Domains of Human Angiostatin,”J. Biol. Chem., 271(46): 29461-29467 (1996).
Castellino, F.J., and S.G. McCance, “The kringle domains of human plasminogen,”Ciba Found. Symp., 212: 46-65 (1997).
Chang, Y., et al., “Structure and Ligand Binding Determinants of the Recombinant Kringle 5 Domain of Human Plasminogen,”Biochemistry, 37: 3258-3271 (1998).
Chase, T. and E. Shaw, “Titration of Trypsin, Plasmin, and Thrombin with p-Nitrophenyl {acute over (p)}-Guanidinobenzoate HCI,”Methods Enzymol., 19: 20-27 (1970).
Cunningham, B.C., and J.A. Wells, “High-Resolution Epitope Mapping of hGH-Receptor Interactions by Alanine-Scanning Mutagenesis,”Science, 244: 1081-1085 (1989).
de Vos, A.M., et al., “HumanGrowth Hormone and Extracellular Domain of Its Receptor: Crystal Structure of the Complex,” Science, 255: 306-312 (1992).
Douglas, J.T., et al., “The Two-Domain NK1 Fragment of Plasminogen: Flding, Ligand Binding, and Thermal Stability Profile,”Biochemistry, 41(10): 3302-3310 (2002).
Goretzki, L., et al., “Binding of the NG2 Proteoglycan to Kringle Domains Modulates the Functional Properties of Angiostatin and Plasmin (ogen),”J. Biol. Chem., 275(37): 28625-28633 (2000).
Gribskov, M., and Richard R. Burgess, “Sigma factors fromE. coli, B. subtilis, phage SP01, and phage T4 are homologous proteins,”Nucl. Acids Res., 14(6): 6745-6763 (1986).
Hoover, G.J., et al., “Amino Acids of the Recombinant Kringle 1 Domain of Human Plasminogen that Stabilize Its Interaction with ω-Amino Acids,”Biochemistry, 32(41): 10936-10943 (1993).
Houghten, R.A., “General method for the rapid solid-phase synthesis of large numbers of peptides: Specificity of antigen-antibody interaction at the level of individual amino acids,”Proc. Natl. Acad. Sci. USA, 82: 5131-5135 (1985).
Johanson, K., et al., “Binding Interactions of Human Interleukin 5 with Its Receptor α Subunit,”J. Biol. Chem., 270(16): 9459-9471 (1995).
Kolev, K., et al., “Functional Evaluation of the Structural Features of Proteases and Their Substrate in Fibrin Surface De tradation,”J. Biol. Chem., 272(21): 13666-75 (1997).
Komorowicz, E., et al., “Fibrinolysis with Des-Kringle Derivatives of Plasmin and Its Modulation by Plasma Protease Inhibitors,”Biochemistry, 37(25): 9112-9118 (1998).
Lee, H., et al., “Disruption of Interkringle Disulfide Bond of Plasminogen Kringle 1-3 Changes the Lysine Binding Capability of Kringle 2, But Not Its Antiangiogenic Activity,”Arch. Biochem. Biophys., 375(2): 359-363 (2000).
Lerch, P.G., et al., “Localization of Individual Lysine-Binding Regions in Human Plasminogen and Investigations on Their Complex-Forming Properties,”Eur. J. Biochem., 107(1): 7-13 (1980).
Lin, L-F., et al., “Epsilon Amino Caproic Acid Inhibits Streptokinase—Plasminogen Activator Complex Formation and Substrate Binding through Kringle-Dependent Mechanisms,”Biochemistry, 39: 4740-4745 (2000).
Lucas, M.A., et al., “The Binding of Human Plasminogen to Fibrin and Fibrinogen,”J. Biol. Chem., 258(7): 4249-4256 (1983).
Marder, V.J., et al., “Plasmin Induces Local Thrombolysis without Causing Hemorrhage: A Comparison with Tissue Plasminogen Activator in the Rabbit,”Thromb. Haemost., 86(3): 739-745 (2001).
Matsuka, Y.V., et al., “Fluorescence spectroscopic analysis of ligand binding to kringle 1+2+3 and kringle 1 fragments from human plasminogen,”Eur. J. Biochem., 190: 93-97 (1990).
McCance, S., et al., “Amino Acid Residues of the Kringle-4 and Kringle-5 Domains of Human Plasminogen that Stabilize their Interactions with ω-Amino Acid Ligands,”J. Biol. Chem., 269(51): 32405-32410 (1994).
Menhart, N., et al., “Functional Independence of the Kringle 4 and Kringle 5 Regions of Human Plasminogen,”Biochemistry, 32: 8799-8806 (1993).
Motta, A., et al., “Complete Assignment of the Aromatic Proton Magnetic Resonance Spectrum of the Kringle 1 Domain from Human Plasminogen: Structure of the Ligand-Binding Site,”Biochemistry, 26(13): 3827-3836 (1987).
Novokhatny, V., et al., “Thrombolytic potency of acid-stabilized plasmin: superiority over tissue-type plasminogen activator in an in vitro model of catheter-assisted thrombolysis,”J. Thromb. Haemost., 1(5): 1034-1041 (2003).
Novokhatny, V., and Stanislav A. Kudinov, “Domains in Human Plasminogen,”J. Mol. Biol., 179: 215-232 (1984).
Novokhatny, V., et al., “Analysis of Ligand Binding to Kringles 4 and 5 Fragments from Human Plasminogen,”Thromb Res., 53(3): 243-52 (1989).
Powell, J.R., and Francis J. Castellino, “Activation of Human Neo-Plasminogen-Val442by Urokinase and Streptokinase and a Kinetic Characterization of Neo-Plasmin-Val442”J. Biol. Chem., 255(11): 5329-5335 (1990).
Rejante, M.R. and M. Llinas, “Solution structure of the ε-aminohexanoic acid complex of human plasminogen kringle 1,”Eur. J. Biochem., 221(3): 939-949 (1994).
Schwartz, R.M., and M.O. Dayhoff, “M

Affiliated with

Also associated with

Rating

Recombinantly modified plasmin does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Recombinantly modified plasmin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinantly modified plasmin will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4280506